Literature DB >> 10732786

Activation of p53 by oncogenes.

S W Lowe1.   

Abstract

p53 is activated by a variety of cellular stresses, including DNA damage, hypoxia, and mitogenic oncogenes, but the extent to which each signal engages p53 as a tumour suppressor remains unknown. In non-immortal cells, the adenovirus E1A oncogene activates p53 to promote apoptosis, whereas oncogenic ras activates p53 to promote cellular senescence. Inactivation of p53 prevents E1A-induced apoptosis or Ras-induced senescence, allowing proliferation to continue unabated. In each instance, the ability of the oncogene to activate p53 involves the same functions as are required for their transforming potential, implying that p53 activation acts as a fail-safe mechanism to counter hyperproliferative signals. Furthermore, p19(ARF) is strictly required for oncogene signalling to p53. The fact that ARF--itself a tumour suppressor--acts as an intermediary in this response argues that the tumour suppressor activity of p53 can arise from its ability to eliminate oncogene-expressing cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10732786     DOI: 10.1677/erc.0.0060045

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  31 in total

1.  Inactivation of p21 by E1A leads to the induction of apoptosis in DNA-damaged cells.

Authors:  D Chattopadhyay; M K Ghosh; A Mal; M L Harter
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

2.  The p53-Bcl-2 connection.

Authors:  M T Hemann; S W Lowe
Journal:  Cell Death Differ       Date:  2006-05-19       Impact factor: 15.828

3.  Inappropriate activation of cyclin-dependent kinases by the phosphatase Cdc25b results in premature mitotic entry and triggers a p53-dependent checkpoint.

Authors:  Shohreh Varmeh; James J Manfredi
Journal:  J Biol Chem       Date:  2009-01-09       Impact factor: 5.157

4.  Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes.

Authors:  G H Fisher; S L Wellen; D Klimstra; J M Lenczowski; J W Tichelaar; M J Lizak; J A Whitsett; A Koretsky; H E Varmus
Journal:  Genes Dev       Date:  2001-12-15       Impact factor: 11.361

5.  Combining p53 stabilizers with metformin induces synergistic apoptosis through regulation of energy metabolism in castration-resistant prostate cancer.

Authors:  Long Chen; Nihal Ahmad; Xiaoqi Liu
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

6.  Ral GTPase down-regulation stabilizes and reactivates p53 to inhibit malignant transformation.

Authors:  Awet Tecleab; Xiaolei Zhang; Said M Sebti
Journal:  J Biol Chem       Date:  2014-09-10       Impact factor: 5.157

7.  Regulation of the activity of p38 mitogen-activated protein kinase by Akt in cancer and adenoviral protein E1A-mediated sensitization to apoptosis.

Authors:  Yong Liao; Mien-Chie Hung
Journal:  Mol Cell Biol       Date:  2003-10       Impact factor: 4.272

8.  Physical interaction of tumour suppressor p53/p73 with CCAAT-binding transcription factor 2 (CTF2) and differential regulation of human high-mobility group 1 (HMG1) gene expression.

Authors:  Hidetaka Uramoto; Hiroto Izumi; Gunji Nagatani; Haruki Ohmori; Naofumi Nagasue; Tomoko Ise; Takeshi Yoshida; Kosei Yasumoto; Kimitoshi Kohno
Journal:  Biochem J       Date:  2003-04-15       Impact factor: 3.857

9.  Triterpenoids from Glycine max decrease invasiveness and induce caspase-mediated cell death in human SNB19 glioma cells.

Authors:  Niranjan Yanamandra; Mark A Berhow; Santhi Konduri; Dzung H Dinh; William C Olivero; Garth L Nicolson; Jasti S Rao
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

10.  Silencing of the Lats2 tumor suppressor overrides a p53-dependent oncogenic stress checkpoint and enables mutant H-Ras-driven cell transformation.

Authors:  Y Aylon; N Yabuta; H Besserglick; Y Buganim; V Rotter; H Nojima; M Oren
Journal:  Oncogene       Date:  2009-10-26       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.